Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    July 2017

  1. Retraction: Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor-CTL Interaction.
    Cancer Res. 2017;77:3718.
    PubMed     Text format    


    June 2017
  2. REINHARDT J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, et al
    MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy.
    Cancer Res. 2017 Jun 26. pii: canres.0395.2017.
    PubMed     Text format     Abstract available


  3. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Text format     Abstract available


    May 2017

  4. Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Cancer Res. 2017;77:2770.
    PubMed     Text format    


  5. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Text format     Abstract available


    April 2017
  6. WANG H, Schaefer T, Konantz M, Braun M, et al
    Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.
    Cancer Res. 2017;77:2148-2160.
    PubMed     Text format     Abstract available


  7. SANSONE P, Berishaj M, Rajasekhar VK, Ceccarelli C, et al
    Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.
    Cancer Res. 2017;77:1927-1941.
    PubMed     Text format     Abstract available


    March 2017
  8. LIAO L, Song M, Li X, Tang L, et al
    E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
    Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
    PubMed     Text format     Abstract available



  9. Correction: Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Cancer Res. 2017;77:1505.
    PubMed     Text format    


    February 2017
  10. RUPRECHT B, Zaal EA, Zecha J, Wu W, et al
    Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis.
    Cancer Res. 2017 Feb 16. pii: canres.2976.2016.
    PubMed     Text format     Abstract available


  11. STEINBERG SM, Shabaneh T, Zhang P, Martyanov V, et al
    Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.1755.2016.
    PubMed     Text format     Abstract available


  12. JACKSON W, Sosnoski DM, Ohanessian SE, Chandler P, et al
    The Role of Megakaryocytes in Breast Cancer Metastasis to Bone.
    Cancer Res. 2017 Feb 15. pii: canres.1084.2016.
    PubMed     Text format     Abstract available


    January 2017
  13. ZHANG T, Xu M, Makowski MM, Lee C, et al
    SDHD promoter mutations ablate GABP transcription factor binding in melanoma.
    Cancer Res. 2017 Jan 20. pii: canres.0919.2016.
    PubMed     Text format     Abstract available


  14. NEUBERT NJ, Tille L, Barras D, Soneson C, et al
    Broad and conserved immune regulation by genetically heterogeneous melanoma cells.
    Cancer Res. 2017 Jan 19. pii: canres.2680.2016.
    PubMed     Text format     Abstract available


    November 2016
  15. JOYCE CE, Yanez AG, Mori A, Yoda A, et al
    Differential regulation of the melanoma proteome by eIF4A1 and eIF4E.
    Cancer Res. 2016 Nov 22. pii: canres.1298.2016.
    PubMed     Text format     Abstract available


  16. AZAN A, Caspers PJ, Bakker Schut TC, Roy S, et al
    A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
    Cancer Res. 2016 Nov 11. pii: canres.1733.2016.
    PubMed     Text format     Abstract available


    September 2016
  17. XIA T, Konno H, Barber GN
    Recurrent loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
    Cancer Res. 2016 Sep 28. pii: canres.1404.2016.
    PubMed     Text format     Abstract available


  18. KIM M, Neznanov N, Wilfong CD, Fleyshman DI, et al
    Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas.
    Cancer Res. 2016 Sep 28. pii: canres.2764.2015.
    PubMed     Text format     Abstract available


  19. SATOW R, Nakamura T, Kato C, Endo M, et al
    ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3.
    Cancer Res. 2016 Sep 26. pii: canres.0991.2016.
    PubMed     Text format     Abstract available


  20. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available


  21. KLARQUIST J, Tobin K, Farhangi Oskuei P, Henning SW, et al
    CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA.
    Cancer Res. 2016 Sep 12. pii: canres.0618.2016.
    PubMed     Text format     Abstract available


  22. TAKAHASHI N, Sugaya M, Suga H, Oka T, et al
    Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T cell lymphoma.
    Cancer Res. 2016 Sep 6. pii: canres.0992.2016.
    PubMed     Text format     Abstract available


    August 2016
  23. TEH JL, Purwin TJ, Greenawalt EJ, Chervoneva I, et al
    An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma.
    Cancer Res. 2016 Aug 3. pii: canres.3384.2015.
    PubMed     Text format     Abstract available


    June 2016
  24. ORSO F, Quirico L, Virga F, Penna E, et al
    miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer.
    Cancer Res. 2016 Jun 21. pii: canres.1322.2015.
    PubMed     Text format     Abstract available


  25. BAKDASH G, Buschow SI, Gorris M, Halilovic A, et al
    Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines.
    Cancer Res. 2016 Jun 20. pii: canres.1695.2015.
    PubMed     Text format     Abstract available


  26. BOYLE SE, Fedele CG, Corbin V, Wybacz E, et al
    CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  27. ZHAO F, Sucker A, Horn S, Heeke C, et al
    Melanoma lesions independently acquire T-cell resistance during metastatic latency.
    Cancer Res. 2016 Jun 3. pii: canres.0008.2016.
    PubMed     Text format     Abstract available


  28. SCHWARTZ H, Blacher E, Amer M, Livneh N, et al
    Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation.
    Cancer Res. 2016 Jun 3. pii: canres.0485.2016.
    PubMed     Text format     Abstract available


    May 2016
  29. HARBST K, Lauss M, Cirenajwis H, Isaksson K, et al
    Multi-region whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma.
    Cancer Res. 2016 May 23. pii: canres.3476.2016.
    PubMed     Text format     Abstract available


  30. LAZAR I, Clement E, Dauvillier S, Milhas D, et al
    Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer.
    Cancer Res. 2016 May 23. pii: canres.0651.2016.
    PubMed     Text format     Abstract available


  31. YAMADA K, Uchiyama A, Uehara A, Perera B, et al
    MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages.
    Cancer Res. 2016 May 17. pii: canres.2812.2015.
    PubMed     Text format     Abstract available


  32. HOLLANDER L, Guo X, Velazquez H, Chang J, et al
    Renalase expression by melanoma and tumor associated-macrophages promotes tumor growth through a STAT3-mediated mechanism.
    Cancer Res. 2016 May 9. pii: canres.1524.2015.
    PubMed     Text format     Abstract available


    April 2016
  33. NEVALA WK, Buhrow SA, Knauer DJ, Reid JM, et al
    Antibody Targeted Chemotherapy for the Treatment of Melanoma.
    Cancer Res. 2016 Apr 28. pii: canres.3131.2015.
    PubMed     Text format     Abstract available


  34. WEBER CE, Luo C, Hotz-Wagenblatt A, Gardyan A, et al
    miR-339-3p is a tumor suppressor in melanoma.
    Cancer Res. 2016 Apr 15. pii: canres.2932.2015.
    PubMed     Text format     Abstract available


  35. LIM S, Liu H, Madeira da Silva L, Arora R, et al
    Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1alpha.
    Cancer Res. 2016;76:2231-42.
    PubMed     Text format     Abstract available


  36. VASATURO A, Halilovic A, Bol KF, Verweij DI, et al
    T cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines.
    Cancer Res. 2016 Apr 11. pii: canres.3211.2015.
    PubMed     Text format     Abstract available


    March 2016
  37. HERRERA-ABREU MT, Palafox M, Asghar U, Rivas MA, et al
    Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  38. NIKOLAI BC, Lanz RB, York B, Dasgupta S, et al
    HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.
    Cancer Res. 2016;76:1463-75.
    PubMed     Text format     Abstract available


  39. BOUSSEMART L, Girault I, Malka-Mahieu H, Mateus C, et al
    Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.
    Cancer Res. 2016;76:1476-84.
    PubMed     Text format     Abstract available


  40. JONES LM, Broz ML, Ranger JJ, Ozcelik J, et al
    STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.
    Cancer Res. 2016;76:1416-28.
    PubMed     Text format     Abstract available


  41. JOHNSON N, De Ieso P, Migliorini G, Orr N, et al
    Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  42. HUH SJ, Oh H, Peterson MA, Almendro V, et al
    The proliferative activity of mammary epithelial cells in normal tissue predicts breast cancer risk in premenopausal women.
    Cancer Res. 2016 Mar 3. pii: canres.1927.2015.
    PubMed     Text format     Abstract available


  43. NAKANISHI Y, Walter K, Spoerke JM, O'Brien C, et al
    Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110beta.
    Cancer Res. 2016;76:1193-203.
    PubMed     Text format     Abstract available


    February 2016
  44. LUCENAY KS, Doostan I, Karakas C, Bui T, et al
    Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells.
    Cancer Res. 2016 Feb 29. pii: canres.1646.2015.
    PubMed     Text format     Abstract available


  45. JIANG YZ, Liu YR, Xu XE, Jin X, et al
    Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value.
    Cancer Res. 2016 Feb 26. pii: canres.3284.2015.
    PubMed     Text format     Abstract available


  46. DEN HOLLANDER P, Rawls K, Tsimelzon A, Shepherd J, et al
    Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival.
    Cancer Res. 2016 Feb 26. pii: canres.0673.2014.
    PubMed     Text format     Abstract available


  47. SAHA S, Mukherjee S, Khan P, Kajal K, et al
    Aspirin suppresses the acquisition of chemo-resistance in breast cancer by disrupting an NFkappaB-IL6 signaling axis responsible for the generation of cancer stem cells.
    Cancer Res. 2016 Feb 3. pii: canres.1360.2015.
    PubMed     Text format     Abstract available


  48. NAKAJIMA K, Kho DH, Yanagawa T, Harazono Y, et al
    Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis.
    Cancer Res. 2016 Feb 2. pii: canres.1793.2015.
    PubMed     Text format     Abstract available


  49. LU W, Ning H, Gu L, Peng H, et al
    MCPIP1 selectively destabilizes transcripts associated with an anti-apoptotic gene expression program in breast cancer cells that can elicit complete tumor regression.
    Cancer Res. 2016 Feb 1. pii: canres.1115.2015.
    PubMed     Text format     Abstract available


  50. YOUNGBLOOD VM, Kim LC, Edwards DN, Hwang Y, et al
    The ephrin-A1/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer.
    Cancer Res. 2016 Feb 1. pii: canres.0847.2015.
    PubMed     Text format     Abstract available


    January 2016
  51. REGAN ANDERSON TM, Ma SH, Raj GV, Cidlowski JA, et al
    Breast Tumor Kinase (Brk/PTK6) is Induced by HIF, Glucocorticoid Receptor and PELP1 Mediated Stress Signaling in Triple-Negative Breast Cancer.
    Cancer Res. 2016 Jan 29. pii: canres.2510.2015.
    PubMed     Text format     Abstract available


  52. ZHAO W, Prijic S, Urban BC, Tisza MJ, et al
    Candidate anti-metastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity.
    Cancer Res. 2016 Jan 29. pii: canres.1970.2015.
    PubMed     Text format     Abstract available


  53. BACCI M, Giannoni E, Fearns A, Ribas R, et al
    miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors.
    Cancer Res. 2016 Jan 21. pii: canres.2038.2015.
    PubMed     Text format     Abstract available


  54. CAMP NJ, Lin WY, Bigelow A, Burghel GJ, et al
    Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus.
    Cancer Res. 2016 Jan 21. pii: canres.1629.2015.
    PubMed     Text format     Abstract available


  55. MERINO VF, Nguyen N, Jin K, Sadik H, et al
    Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer.
    Cancer Res. 2016 Jan 19. pii: canres.1619.2015.
    PubMed     Text format     Abstract available


  56. COX TR, Gartland A, Erler JT
    Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.
    Cancer Res. 2016;76:188-92.
    PubMed     Text format     Abstract available


  57. TANAKA M, Shimamura S, Kuriyama S, Maeda D, et al
    SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression.
    Cancer Res. 2016;76:358-69.
    PubMed     Text format     Abstract available


  58. LIM SO, Li CW, Xia W, Lee HH, et al
    EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape.
    Cancer Res. 2016 Jan 12. pii: canres.2478.2015.
    PubMed     Text format     Abstract available


  59. LI CW, Xia W, Lim SO, Hsu JL, et al
    AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation.
    Cancer Res. 2016 Jan 12. pii: canres.1941.2015.
    PubMed     Text format     Abstract available


  60. ESPELIN CW, Leonard SC, Geretti E, Wickham TJ, et al
    Dual HER2 targeting with trastuzumab and liposome-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer.
    Cancer Res. 2016 Jan 12. pii: canres.1518.2015.
    PubMed     Text format     Abstract available


  61. JIANG L, Yu L, Zhang X, Lei F, et al
    miR-892b silencing activates NF-kappaB and promotes aggressiveness in breast cancer.
    Cancer Res. 2016 Jan 8. pii: canres.1770.2015.
    PubMed     Text format     Abstract available


  62. MITTAL D, Caramia F, Michiels S, Joensuu H, et al
    Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  63. PICON-RUIZ M, Pan C, Drews-Elger K, Jang K, et al
    Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  64. JIANG Y, Pan Y, Rhea PR, Tan L, et al
    A Sucrose-Enriched Diet Promotes Tumorigenesis in Mammary Gland in Part through the 12-Lipoxygenase Pathway.
    Cancer Res. 2016;76:24-9.
    PubMed     Text format     Abstract available


    December 2015
  65. BHOLA NE, Jansen VM, Koch JP, Li H, et al
    Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population.
    Cancer Res. 2015 Dec 16. pii: canres.1640.2015.
    PubMed     Text format     Abstract available


  66. JIANG H, Sun HF, Gao SP, Li LD, et al
    SSBP1 Suppresses TGF-beta-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling.
    Cancer Res. 2015 Dec 16. pii: canres.1630.2015.
    PubMed     Text format     Abstract available


  67. ADAMS BD, Wali VB, Cheng CJ, Inukai S, et al
    miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple Negative Breast Cancer.
    Cancer Res. 2015 Dec 16. pii: canres.2321.2015.
    PubMed     Text format     Abstract available


  68. RANJAN A, Gupta P, Srivastava SK
    Penfluridol: An antipsychotic agent suppresses metastatic tumor growth in triple negative breast cancer by inhibiting integrin signaling axis.
    Cancer Res. 2015 Dec 1. pii: canres.1233.2015.
    PubMed     Text format     Abstract available


    November 2015
  69. YUZEFOVYCH LV, Kahn AG, Schuler MA, Eide L, et al
    Mitochondrial DNA repair through OGG1 activity attenuates breast cancer progression and metastasis.
    Cancer Res. 2015 Nov 19. pii: canres.0692.2015.
    PubMed     Text format     Abstract available


  70. LANZARDO S, Conti L, Rooke R, Ruiu R, et al
    Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer.
    Cancer Res. 2015 Nov 13. pii: canres.1208.2015.
    PubMed     Text format     Abstract available


  71. JOSEFSSON A, Nedrow JR, Park S, Ray Banerjee S, et al
    Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer.
    Cancer Res. 2015 Nov 10. pii: canres.2141.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: